Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Halozyme Therapeutics Inc

Current price
39.95 USD -0.07 USD (-0.17%)
Last closed 39.97 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 5 242 969 600 USD
Yield for 12 month -29.83 %
21.11.2021 - 28.11.2021

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. Address: 11388 Sorrento Valley Road, San Diego, CA, United States, 92121


WallStreet Target Price

51.27 USD

P/E ratio


Dividend Yield

3.06 %

Current Year

+660 116 000 USD

Last Year

+443 310 000 USD

Current Quarter

+216 033 000 USD

Last Quarter

+221 038 000 USD

Current Year

+520 812 000 USD

Last Year

+361 897 000 USD

Current Quarter

+161 210 000 USD

Last Quarter

+170 968 000 USD

Key Figures HALO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 396 224 992 USD
Operating Margin TTM 42.02 %
PE Ratio 21.2246
Return On Assets TTM 11.08 %
PEG Ratio -2.5
Return On Equity TTM 146.7 %
Wall Street Target Price 51.27 USD
Revenue TTM 780 710 016 USD
Book Value 1.89 USD
Revenue Per Share TTM 5.85 USD
Dividend Share
Quarterly Revenue Growth YOY 3.4 %
Dividend Yield 3.06 %
Gross Profit TTM 454 205 000 USD
Earnings Share 1.87 USD
Diluted Eps TTM 1.87 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY 38.6 %
Profit Margin 32.52 %

Dividend Analytics HALO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History HALO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 3.06 %
Last Split Factor 171:40
Payout Ratio
Last Split Date 10.12.2003
Dividend Date

Stock Valuation HALO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 21.2246
Forward PE 9.6993
Enterprise Value Revenue 8.0863
Price Sales TTM 6.7156
Enterprise Value EBITDA 16.1065
Price Book MRQ 21.0355

Financials HALO

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators HALO

For 52 weeks

29.85 USD 59.4 USD
50 Day MA 37.34 USD
Shares Short Prior Month 6 570 769
200 Day MA 38.16 USD
Short Ratio 6.92
Shares Short 6 974 433
Short Percent 6.24 %